UK Medicines Information
daratumumab (Darzalex)
Information type:
Drug best practice guidance
Source:
Scottish Medicines Consortium
Specialities:
Cancers | Haematological disorders
Summary
The SMC does not recommend daratumumab as monotherapy for adults with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
UKMi comment
The company did not present a robust economic analysis to gain acceptance.
Related links: